Theory Paper IIIDrNB Cardiology – Theory Notes

CLINICAL SCENARIOS FOR MECHANICAL CIRCULATORY SUPPORT (MCS)

2-page exam answerLast reviewed: October 2026
Merit MedScript seal

ITHE INTERMACS AND SCAI SHOCK CLASSIFICATIONS (THE TRIAGE GOLD STANDARDS)

  • The INTERMACS 7-Profile Classification (For Advanced NYHA Class IIIb–IV Heart Failure): Stratifies advanced heart failure urgency and guides the selection between Temporary (Short-Term) MCS versus Durable (Long-Term) Left Ventricular Assist Devices (LVAD):
INTERMACS Profile Clinical Shorthand (“Catchphrase”) Hemodynamic & Clinical Definition Recommended MCS / Timeline
Profile 1 “Critical Cardiogenic Shock (Crash and Burn)” Life-threatening hypotension despite rapidly escalating inotropes/vasopressors and critical organ hypoperfusion (worsening acidosis/lactate, anuria; corresponds to SCAI Stage D/E) Immediate Temporary MCS (Impella, VA-ECMO, or ECPELLA) within minutes to hours (do not implant durable LVAD directly in Profile 1 due to high mortality)
Profile 2 “Progressive Decline (Sliding on Inotropes)” Dependent on continuous IV inotropes with deteriorating renal function, hepatic congestion, nutrition, or volume status Definitive intervention (Durable LVAD or Urgent Transplant) within a few days
Profile 3 “Stable but Inotrope-Dependent” Hemodynamically stable on mild-to-moderate IV inotropes (in hospital or home), but repeated weaning attempts fail due to hypotension, symptoms, or rising creatinine Elective Durable LVAD (HeartMate 3) or Transplant within a few weeks (Ideal Durable LVAD Window)
Profile 4 “Resting Symptoms at Home on Oral Therapy” Ambulatory on oral therapy but experiences daily resting/minimal-exertion congestion and “frequent-flier” ER/hospital readmissions Evaluate for Durable LVAD or Transplant within weeks to a few months
Profile 5 “Exertion Intolerant (Housebound)” Comfortable at rest, unable to engage in any activity, living predominantly within the house/bed-to-chair Optimize GDMT/CRT; serial CPET and transplant/LVAD evaluation
Profile 6 “Exertion Limited (Walking Wounded)” Minor-exertion fatigue within a few blocks, able to leave the house briefly Medical optimization (Durable LVAD generally not indicated)
Profile 7 “Advanced NYHA Class III” Clinically stable with reasonable activity level, history of recent decompensation Medical management

IISCENARIO 1: ACUTE CARDIOGENIC SHOCK — “BRIDGE TO RECOVERY” OR “BRIDGE TO DECISION”

  • Clinical Settings: AMI-Related Cardiogenic Shock (AMI-CS), Fulminant Myocarditis (lymphocytic or giant cell), Peripartum Cardiomyopathy, Takotsubo Syndrome, or Post-Cardiotomy Shock.
  • Guideline Stance and Landmark Trial Shifts (ESC 2021/2023 HF & ACC/AHA 2022):
    • Downgrading of Routine IABP in AMI-CS (Class III — No Benefit): Based on the IABP-SHOCK II Trial (NEJM 2012; n = 600), routine Intra-Aortic Balloon Pump (IABP) placement in AMI-CS does not reduce 30-day, 1-year, or 6-year mortality; in contemporary ESC guidelines, IABP is reserved specifically for mechanical complications of AMI (Class IIa for acute mitral regurgitation or ventricular septal rupture) or non-ischemic ADHF bridge.
    • Microaxial Flow Pump (Impella CP) Survival Breakthrough — The DanGer Shock Trial (NEJM 2024): Randomized 355 patients with STEMI complicated by Cardiogenic Shock (SCAI Stage C/D/E, arterial lactate >=2.5 mmol/L, LVEF <45%, excluding comatose post-arrest patients) to Impella CP + Standard Care versus Standard Care Alone. Impella CP significantly reduced 180-day all-cause mortality from 58.5 percent to 45.8 percent (Absolute Risk Reduction 12.7%; HR 0.74; p = 0.04; NNT = 8)—providing the first randomized trial proof in 25 years (since the 1999 SHOCK Trial) that an active temporary MCS device reduces mortality in AMI-CS (despite higher rates of limb ischemia and renal replacement therapy).
    • Routine Early VA-ECMO in AMI-CS — The ECLS-SHOCK Trial (NEJM 2023): Randomized 420 patients with AMI-CS (78% of whom had resuscitated cardiac arrest) to early routine VA-ECMO versus medical therapy alone; routine VA-ECMO did NOT reduce 30-day mortality (47.8% vs. 49.0%; p = 0.81) and doubled major bleeding and peripheral vascular complications. Consequently, VA-ECMO is reserved for refractory biventricular arrest (ECPR), severe hypoxemic respiratory failure, or INTERMACS 1 crash-and-burn as a “Bridge to Decision” (often requiring LV venting via Impella [“ECPELLA”] or IABP because retrograde aortic ECMO flow increases LV afterload and causes pulmonary edema/aortic root thrombosis).

IIISCENARIO 2: HIGH-RISK PERCUTANEOUS CORONARY INTERVENTION (“PROTECTED PCI”)

  • Clinical Setting: Complex multivessel, unprotected Left Main, or last-remaining-vessel PCI (often requiring rotational atherectomy/IVL) in patients with severe LV systolic dysfunction (LVEF <=30 to 35%) who are turned down for CABG.
  • Evidence (BCIS-1 and PROTECT II Trials): In PROTECT II (Circulation 2012), prophylactic Impella 2.5 (providing 2.5 L/min active forward flow and direct LV unloading) vs. IABP in complex PCI with LVEF <=35% showed similar 30-day intent-to-treat MACE, but significantly lower 90-day MACE in the per-protocol analysis (40.0% vs. 51.0%; p = 0.023) by preventing intraprocedural hemodynamic collapse during prolonged balloon/atherectomy runs (ongoing PROTECT IV RCT is testing Impella CP/5.5 in CHIP).

IVSCENARIOS 3, 4 & 5: DURABLE LEFT VENTRICULAR ASSIST DEVICES (LVAD — HEARTMATE 3)

  • Abandonment of Historical “BTT vs. DT” Silos (MOMENTUM 3 Trial Paradigm): While durable LVADs are implanted clinically as Bridge to Transplant (BTT) (for listed candidates deteriorating at INTERMACS 2–3), Bridge to Candidacy (BTC) (to reverse “fixed” secondary pulmonary hypertension [PVR >5 WU] or cardiorenal dysfunction so the patient can become transplant-eligible), or Destination Therapy (DT) (lifelong support in transplant-ineligible patients aged >70 years or with recent malignancy/obesity), the MOMENTUM 3 Trial proved that clinical outcomes are identical across BTT, BTC, and DT categories.
  • Eligibility Criteria for Durable LVAD (ESC 2021 / AHA-ACC 2022 Class I for Inotrope-Dependent; Class IIa for Ambulatory Advanced HF): Persistent NYHA Class IV symptoms for >=60–90 days despite optimal GDMT/CRT, LVEF <25%, Peak VO2 <12 mL/kg/min, and at least one of: inotrope/temporary MCS dependency (INTERMACS 2–3), >=3 HF hospitalizations in 12 months, or progressive end-organ renal/hepatic dysfunction—in the absence of severe irreversible Right Ventricular Failure.
  • Landmark Trial — MOMENTUM 3 (NEJM 2019 & 5-Year Extended Results, Mehra et al., JAMA 2022):
  • Design: Randomized 1,028 advanced HFrEF patients to the HeartMate 3 (fully magnetically levitated [Full MagLev] centrifugal-flow pump with wide blood-flow gaps, frictionless rotor, and intrinsic artificial pulse every 2 seconds) versus the HeartMate II (mechanical-bearing axial-flow pump).
  • Results: HeartMate 3 significantly improved the 2-year primary composite endpoint (survival free of disabling stroke or reoperation to replace/remove a malfunctioning pump: 76.9% vs. 64.8% in the final report), virtually eliminated pump thrombosis (1.4% vs. 13.9%), halved stroke rates, and achieved a 5-year overall survival of 58.4 percent (approaching the survival of marginal heart transplant recipients).
  • ARIES-HM3 Trial (JAMA 2023 — Aspirin-Free Antithrombotic Regimen): Demonstrated that in patients with a HeartMate 3 LVAD, eliminating Aspirin and treating with Warfarin (INR 2.0–3.0) alone was non-inferior for thromboembolism (zero pump thrombosis) while reducing non-surgical major bleeding (primarily GI bleeding from acquired von Willebrand syndrome and arteriovenous malformations) by 34 percent.
MCS Device Cannulation & Pump Mechanism Max Flow (L/min) Direct LV Unloading (Reduces LVEDP & MVO2)? Primary Clinical Role
IABP Femoral/axillary descending aorta; counterpulsation 0.5 L/min Mild (reduces afterload) Mechanical AMI complications (acute MR/VSD — Class IIa); neutral in routine AMI-CS (IABP-SHOCK II)
Impella CP / 5.5 Retrograde transaortic (LV to Ascending Aorta); microaxial pump 3.5–4.3 L/min (CP); 5.5–6.0 L/min (5.5) Profound Direct LV Unloading AMI-CS (DanGer Shock: 12.7% mortality ARR), Protected PCI (PROTECT II), or ECPELLA LV vent
TandemHeart Transseptal (Left Atrium to Iliofemoral Artery); centrifugal 4.0–5.0 L/min Indirect (unloads LA; usable with LV thrombus or mechanical aortic valve) Severe LV shock when LV thrombus or mechanical AVR precludes Impella
VA-ECMO Right Atrium/Femoral Vein to Femoral Artery + oxygenator 4.0–7.0 L/min NO (Increases LV Afterload -> requires Impella/IABP vent) Biventricular crash-and-burn (INTERMACS 1), ECPR arrest, or RV failure with hypoxia
HeartMate 3 LVAD Surgical LV Apex to Ascending Aorta; Full MagLev centrifugal Up to 10 L/min Complete Durable LV Unloading BTT, BTC, & Destination Therapy in INTERMACS 2–4 (MOMENTUM 3 & ARIES-HM3)

VPRACTICAL CONSIDERATIONS IN THE INDIAN CLINICAL CONTEXT

  • Resource-Stratified Temporary MCS Selection: Because percutaneous Impella catheters and durable HeartMate 3 LVADs carry prohibitive out-of-pocket costs in India, IABP + Inotropes (in pre-shock / SCAI Stage B–C or acute mechanical complications) and peripheral VA-ECMO (managed by in-house cardiac surgery perfusion teams at a fraction of the disposable catheter cost of Impella) serve as the primary workhorses for acute Bridge-to-Recovery (e.g., fulminant viral/dengue myocarditis, aluminum phosphide poisoning, or post-cardiotomy shock) and Bridge-to-Transplant.

Key references

  • Møller JE, Engstrøm T, Jensen LO, et al. (DanGer Shock Investigators): Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock, New England Journal of Medicine, 2024.
  • Thiele H, Zeymer U, Akin I, et al. (ECLS-SHOCK Investigators): Extracorporeal Life Support in Infarct-Related Cardiogenic Shock, New England Journal of Medicine, 2023.
  • Mehra MR, Uriel N, Naka Y, et al. & Mehra MR, Goldstein DJ, et al. (MOMENTUM 3 Investigators): A Fully Magnetically Levitated Left Ventricular Assist Device — Final Report (NEJM 2019) & Five-Year Outcomes (JAMA 2022).
  • Mehra MR, Netuka I, Uriel N, et al. (ARIES-HM3 Investigators): Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial, JAMA, 2023.
meritmedscript.comDr. Sidhartha Mullapudi

Was this answer useful?

Your rating helps decide which topics to expand next.

Report an error

Spotted something outdated or incorrect? Tell us and we will check it against the source.